Fangxia Wang

Xi'an, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Investigation of Multi-Factor Coupled Aging Mechanisms and Rheological Performance Prediction of Asphalt in Diverse Climatic Regions.

Investigation of Multi-Factor Coupled Aging Mechanisms and Rheological Performance Prediction of Asphalt in Diverse Climatic Regions.

Journal: Materials (Basel, Switzerland)

Published: May 05, 2026

Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Nutritional and immunologic scoring systems to predict complications and outcomes after anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma.

Journal: Cytotherapy

Published: November 13, 2025

Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

Plerixafor Plus G-CSF Versus Etoposide Combined With Cyclophosphamide and G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Single Center Observational Propensity Score-Matched Cohort Study.

Journal: Journal of clinical apheresis

Published: October 13, 2025

Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Comparison of Thrombopoietin Receptor Agonists Plus Recombinant Human Thrombopoietin versus Recombinant Human Thrombopoietin Alone for Hematopoietic Reconstruction in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: October 14, 2024

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA-CAR-T cell therapy: A retrospective study based on LEGEND-2.

Journal: HemaSphere

Published: July 03, 2024

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.

Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia.

Journal: Therapeutic advances in hematology

Published: May 20, 2024

Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.

Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2.

Journal: British journal of haematology

Published: November 02, 2023

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 05, 2023

A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.

A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.

Journal: Hematological oncology

Published: January 09, 2023

Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.

Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: January 23, 2020

CD138- multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient.

CD138- multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient.

Journal: Aging

Published: January 08, 2020

miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells.

miR-582-5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells.

Journal: Cell biology international

Published: December 09, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026